Total Funding
18
27
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
195378
Turning Point Therapeutics is a pharmaceutical company that discovers and develops precision medicines for cancer and other diseases.
Acquired by 
Bristol-Myers Squibb
Siegfried Reich: Executive Vice President, CSOPast Role: Effector Therapeutics, Co-founder & Senior Vice President, Research
J. Jean Cui: Scientific Founder & Board MemberPast Role: Pfizer, Associate Research Fellow
About the Company
Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. They focus on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential
targets regulating the tumor microenvironment and tumor immunity.
Women Founded
